|
Balance Sheet Cash Flow Statement 35 NE Industrial Rd. Branford, CT 06405 CT Tel. 203-488-8201 Fax 203-481-8683 |
Type: Public
On the web:
http://www.neurogen.com
Employees:
30
Employee growth: (79.9%)
Neurogen's goal is for you to sleep peacefully and wake up happy. The drug development firm is investigating new therapies for a number of neurological conditions including restless legs syndrome, Parkinson's disease, and anxiety. Its lead candidate adipiplon is being investigated as a potential treatment for anxiety and has been studied as a treatment for insomnia. Neurogen was founded in 1987, but despite its work and numerous partnerships with larger players, it has yet to produce a marketable product. The usual ups and downs of drug discovery, combined with a sluggish economy, caused Neurogen to lose sleep and consider strategic alternatives until it agreed to be acquired by Ligand Pharmaceuticals.
Key numbers for fiscal year ending December, 2008:
Sales: $3.0M
One year growth: (80.6%)
Net income: ($34.3)M
Officers:
Chairman: Craig A. P. D. Saxton
President, CEO, Secretary, and Director: Stephen R. (Steve) Davis
SVP and Chief Business and Financial Officer: Thomas A. (Tom) Pitler
Competitors:
Boehringer Ingelheim Corporation
DOV Pharmaceutical
Jazz Pharmaceuticals
